secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008282
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports net loss of $81.9M for FY22; cash runway into H2 2025
----------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $472.2M as of Dec 31, 2022; expected to fund operations into H2 2025.
- Net loss of $26.1M in Q4 2022 and $81.9M for full year 2022; R&D expenses $63.7M (FY) vs $35.6M in 2021.
- Pipeline progress: NVL-520 Phase 1 data supportive of best-in-class profile in ROS1+ NSCLC; NVL-655 Phase 1 enrolling; NVL-330 (HER2 exon20) nominated as development candidate.
- Leadership promotions: Henry Pelish to SVP Drug Discovery; John Soglia to SVP Translational Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017023008282/0000950170-23-008282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017023008282/nuvl-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer